NeuroSense (NRSN) news
Recent news
Japan's Onron to buy OnLogic for around 100B yen: Nikkei
AInvest Wire · 2d agoNeuroSense provides update on Nasdaq listing compliance
AInvest Wire · Oct 2, 2026NeuroSense Therapeutics Ltd: H.C. Wainwright adjusts target price to $52 from $8 to reflect 1-for-20 reverse stock split
On September 28, 2026, H.C. Wainwright adjusted its target price for NeuroSense Therapeutics Ltd (NRSN) to $52 from $8, citing the company’s 1-for-20 reverse stock split as a key factor in the revision. The adjustment reflects the split's valuation impact . NeuroSense Therapeutics, a biotechnology…
AInvest Wire · Sep 28, 2026NeuroSense Therapeutics Ltd: To effect reverse share split of co’s ordinary shares at ratio of 1-for-20
NeuroSense Therapeutics Ltd. (NRSN) has announced its intention to execute a reverse share split of its ordinary shares at a ratio of 1-for-20. This action follows the approval by shareholders on August 26, 2026, granting the board authority to implement a reverse share split within a 12-month…
AInvest Wire · Sep 9, 2026NeuroSense Therapeutics Ltd.: H.C. Wainwright initiates coverage with buy rating and target price $8
NeuroSense Therapeutics Ltd. (NRSN) has recently attracted attention from analysts, with H.C. Wainwright initiating coverage on the stock with a "Buy" rating and target price . This recommendation aligns with broader analyst optimism in the healthcare sector, where several firms have highlighted…
AInvest Wire · Sep 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.